Co-Diagnostics
CODX
78 hedge funds and large institutions have $77.6M invested in Co-Diagnostics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 22 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
27% more capital invested
Capital invested by funds: $61M → $77.6M (+$16.6M)
0.09% more ownership
Funds ownership: 0.84% → 0.92% (+0.09%)
11% less funds holding
Funds holding: 88 → 78 (-10)
24% less call options, than puts
Call options by funds: $6.37M | Put options by funds: $8.42M
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.99M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.25M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.81M |
| 4 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
+$1.58M |
| 5 |
Renaissance Technologies
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$1.2M |
| 2 |
E
Ergoteles
New York
|
-$1.13M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.02M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$708K |
| 5 |
Jane Street
New York
|
-$586K |
CODX Hedge Fund Activity: Q3 2021 in Review
78 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q3 2021, worth a combined $77.6M — up 27% from $61M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CODX and 14 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 30 added.
The largest buyer was Millennium Management, adding an estimated $2.99M. The largest seller was Financial Advocates Investment Management, exiting entirely with an estimated $1.2M sold.
- 78 institutional investors held Co-Diagnostics (CODX) as of Q3 2021, down from 88 in Q2 2021.
- Funds reported $77.6M of Co-Diagnostics stock for Q3 2021, up 27% quarter-over-quarter.
- 14 funds opened new Co-Diagnostics positions in Q3 2021 and 22 closed out, a net change of -8 holders.
- The largest Co-Diagnostics buyer in Q3 2021 was Millennium Management, an estimated $2.99M added.
- The largest Co-Diagnostics seller in Q3 2021 was Financial Advocates Investment Management, an estimated $1.2M sold.
Based on aggregated 13F filings for Q3 2021.